MedTrace Logo

Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19

NCT04746339 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 411

Last updated 2022-08-25

No results posted yet for this study

Summary

Randomized, double-blinded, placebo-controlled trial comparing oral anticoagulation with placebo for community-dwelling patients with symptomatic COVID-19 infection and risk factors for thrombosis.

Conditions

Interventions

DRUG

Apixaban 2.5 MG

Apixaban 2.5mg twice daily for 30 days

DRUG

Placebo

placebo twice daily for 30 days

Sponsors & Collaborators

  • Hospital Israelita Albert Einstein

    collaborator OTHER

  • Hospital do Coracao

    collaborator OTHER

  • Hospital Sirio-Libanes

    collaborator OTHER

  • Hospital Moinhos de Vento

    collaborator OTHER

  • Hospital Alemão Oswaldo Cruz

    collaborator OTHER

  • Beneficência Portuguesa de São Paulo

    collaborator OTHER

  • Brazilian Research In Intensive Care Network

    collaborator NETWORK

  • Brazilian Clinical Research Institute

    lead OTHER

Principal Investigators

  • Renato D. Lopes, MD, PhD · BCRI

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-04
Primary Completion
2022-05-13
Completion
2022-05-30

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04746339 on ClinicalTrials.gov